(Q37261949)

19 August 2017

1 reference

title

Screen detected, low volume prostate cancer: the case for active treatment (English)

1 reference

19 August 2017

1 reference

James E Montie

1

1 reference

19 August 2017

publication date

1 September 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

26

1 reference

19 August 2017

issue

5

1 reference

19 August 2017

page(s)

511-515

1 reference

Radical prostatectomy versus watchful waiting in early prostate cancer

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.006

The patient's dilemma: prostate cancer treatment choices

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.006

Confidence and uncertainty long after initial treatment for early prostate cancer: survivors' views of cancer control and the treatment decisions they made.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.006

Do patients with localized prostate cancer treatment really want more aggressive treatment?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.006

Incidence of initial local therapy among men with lower-risk prostate cancer in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.006

Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.006

Survival associated with treatment vs observation of localized prostate cancer in elderly men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.006

Treating older men with prostate cancer: survival (or selection) of the fittest?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.006

Increasing the number of biopsy cores improves the concordance of biopsy Gleason score to prostatectomy Gleason score

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.006

Role of prostate biopsy schemes in accurate prediction of Gleason scores

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.006

Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.006

Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.006

Re-biopsy of the prostate using a stereotactic transperineal technique

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.006

Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.006

Active surveillance for prostate cancer: for whom?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.006

Biological determinants of cancer progression in men with prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.006

Predictive value of primary Gleason pattern 4 in patients with Gleason score 7 tumours treated with radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.006

Expectant management of localized prostatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.006

Predicting life expectancy in men with clinically localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.006

Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.006

Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.006

Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.006

Modeling prostate specific antigen kinetics in patients on active surveillance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.006

Comparison of Methods for Calculating Prostate Specific Antigen Velocity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.006

The male lumpectomy: rationale for a cancer targeted approach for prostate cryoablation. A review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.006

Older patients' willingness to trade off urologic adverse outcomes for a better chance at five-year survival in the clinical setting of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.006

Continued undertreatment of older men with localized prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.006

Patients' preferences for communicating a prostate cancer diagnosis and participating in medical decision-making

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.006

The changing face of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.006

Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.006

Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.006

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.006

10.1016/J.UROLONC.2008.03.006

7 January 2021

Identifiers

DOI

1 reference

19 August 2017

1 reference